Sanofi S.A., FR0000120578

Sanofi stock gains focus as Cheplapharm deal reshapes mature medicines portfolio

Published on 09/19/2026 at 12:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sanofi stock trades around the mid-40 dollar range as of September 18, 2026, while analysts see earnings of 5.07 dollars per share for the current fiscal year. A new strategic partnership with Cheplapharm announced on September 14, 2026 shifts 20 mature medicines and three plants to the German group.

Modern pharmaceutical sterile fill-and-finish manufacturing facility interior with glass vial-filling machines and cleanroom workers in white suits — Sanofi FR0000120578 photorealistic sterile fill-and-finish facility with vial-filling machines and cleanroom workers, Illustration mit AI erstellt.

Sanofi stock (ISIN FR0000120578) is trading in the mid-40 dollar range on Nasdaq as of September 18, 2026, with the shares around 11 percent below their level at the start of 2026 according to MarketBeat data.

Cheplapharm partnership refocuses Sanofi on innovation

On September 14, 2026, Sanofi announced a strategic partnership with German-based Cheplapharm that will transfer responsibility for 20 mature medicines and three manufacturing plants in Hungary, Singapore and France to Cheplapharm in exchange for a 26.4 percent equity stake in the company, as reported by The Globe and Mail.

According to the same report from The Globe and Mail, the portfolio transfer is expected to start in the first quarter of 2027 and conclude by the third quarter of 2027, subject to regulatory approvals and employee consultations, and includes well-known brands such as the anticoagulant Lovenox/Clexane outside the United States.

Earnings momentum and valuation metrics

Sanofi shares are listed on Nasdaq under the ticker SNY, and MarketBeat shows a recent closing price of 43.14 dollars on September 17, 2026, implying a 1.29 percent gain on that trading day with the stock having fallen from 48.46 dollars on January 1, 2026, a decrease of 11.0 percent year to date.

Equities research compiled by MarketBeat indicates that Sanofi delivered earnings per share of 2.41 dollars in its most recently reported quarter, with revenue of 13.36 billion dollars and a net margin of 8.66 percent, while revenue was up 16.0 percent compared with the same quarter a year earlier.

In the same MarketBeat summary, analysts expect Sanofi to post earnings per share of 5.07 dollars for the current fiscal year, providing investors with a benchmark for evaluating the stock against its consensus price target of 49.50 dollars cited in that overview.

According to MarketBeat, the stock currently carries a consensus Hold rating, with the 49.50 dollar target implying upside potential of roughly 14.7 percent from the recent 43.14 dollar closing price.

Stock level and investor perspective

Sanofi stock closed at 42.48 dollars on Nasdaq on September 18, 2026, with a daily decline of 1.53 percent and an after-hours indication of 42.52 dollars according to Yahoo Finance data, leaving the shares trading below the consensus analyst target and reflecting the market's balancing of restructuring benefits and earnings expectations.